REYL & Cie S.A.’s ARK Genomic Revolution ETF ARKG Stock Holding History

REYL & Cie S.A.’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$145K	Buy	+5,460	New	+$174K	0.17%	74

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

REYL & Cie S.A.'s ARKG Position: Q2 2026 in Review

REYL & Cie S.A. opened a new position in ARK Genomic Revolution ETF (ARKG) in Q2 2026: 5,460 shares worth $145K. The stake represents 0.17% of the portfolio and ranks #74 among its holdings.

274 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

REYL & Cie S.A. held 5,460 shares of ARK Genomic Revolution ETF worth $145K as of Q2 2026.
ARK Genomic Revolution ETF was a new REYL & Cie S.A. position in Q2 2026.
ARK Genomic Revolution ETF made up 0.17% of REYL & Cie S.A.'s portfolio in Q2 2026, its #74 holding.
274 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on REYL & Cie S.A.'s 13F filing for Q2 2026, filed 2 Oct 2026.